摘要
Objective:To study the effect of kushenin combined with entecavir therapy on hepatic fibrosis and immune response in patients with chronic hepatitis B.Methods: Patients who were diagnosed with chronic viral hepatitis B in First Affiliated Hospital of PLA General Hospital between March 2015 and June 2017 were enrolled in the study and randomly divided into the experimental group who kushenin combined with entecavir therapy and the control group who received entecavir monotherapy. The levels of hepatic fibrosis indexes and immune cytokines in serum as well as the number of immune cells in peripheral blood were measured before treatment as well as 3 months and 6 months after treatment.Results: Compared with the corresponding indexes of same group before treatment, serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of both groups of patients were significantly lower whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher 3 months and 6 months after treatment;serum PC-III, C-IV, TGF-β1, Ang-II and IFN-γ levels as well as peripheral blood Th1 cell number of experimental group 3 months and 6 months after treatment were significantly lower than those of control group whereas Th2, mDC and pDC cell number as well as CD80 and CD86 expression intensity in peripheral blood as well as IL-5 and IL-10 levels in serum were significantly higher than those of control group.Conclusions: kushenin combined with entecavir treatment of chronic hepatitis B can delay hepatic fibrosis progression and improve immune response.
基金
Youth Science Fund Projects of the Natural Science Foundation of China(No:81600476).
作者简介
Corresponding author:Rui Zhu,Digestive System Department,First Affiliated Hospital of PLA General Hospital,Beijing,100048.Email:zhurui27@126.com.
